Axel Cailleteau

ORCID: 0000-0003-3261-6347
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Breast Cancer Treatment Studies
  • Multiple Myeloma Research and Treatments
  • Prostate Cancer Treatment and Research
  • Medical Imaging Techniques and Applications
  • HER2/EGFR in Cancer Research
  • Cancer therapeutics and mechanisms
  • Hematopoietic Stem Cell Transplantation
  • Lymphoma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • CNS Lymphoma Diagnosis and Treatment
  • Endometrial and Cervical Cancer Treatments
  • Chemotherapy-related skin toxicity
  • Cancer Mechanisms and Therapy
  • Peptidase Inhibition and Analysis
  • Cancer Treatment and Pharmacology
  • Glutathione Transferases and Polymorphisms
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer, Hypoxia, and Metabolism
  • Lung Cancer Research Studies
  • Cancer Risks and Factors
  • Acute Myeloid Leukemia Research
  • CAR-T cell therapy research
  • Eosinophilic Disorders and Syndromes

Institut de Cancérologie de l'Ouest
2021-2024

Institut Génétique Nantes Atlantique
2024

University of Geneva
2024

Assistance Publique – Hôpitaux de Paris
2011

Hôpital Saint-Antoine
2011

Sorbonne Université
2011

Inflammatory breast cancer (IBC) is a rare entity with poor prognosis. We analysed the survival outcomes of patients nonmetastatic IBC and prognostic value tumour or nodal responses to assess their individual impact across subtypes. This retrospective multicentre study included diagnosed between 2010 2017 account for advances in neoadjuvant systemic therapies modern radiotherapy at seven oncology centres France. Three hundred seventeen were analysed. After median follow-up 52 months, 5-year...

10.3390/cancers14163928 article EN Cancers 2022-08-15

We present the case of a 53-year-old woman treated with analgesic radiotherapy for multiple myeloma bone lesion forearm. After first fraction 5 Gray (Gy), she presented an acute respiratory syndrome fever few hours after treatment. The same symptoms occurred second 3 days later. patient recovered quickly thanks to intravenous hydration and suspension radiotherapy. Biological tests revealed tumor lysis syndrome. concluded that clinical could be defined as cytokine release This is time in...

10.1016/j.ctro.2021.11.004 article EN cc-by-nc-nd Clinical and Translational Radiation Oncology 2021-11-12

Although salvage prostate bed radiotherapy is highly effective in biochemically-relapsing cancer patients following prostatectomy, relapses remain frequent and improvements are needed. Randomized phase 3 trials have shown the benefit of adding androgen-depriving therapy to irradiation, but not all from this combination. Preclinical studies that novel agents targeting androgen receptor, DNA repair, PI3K/AKT/mTOR pathways, or hypoxic microenvironment may help increase response irradiation...

10.3389/fonc.2021.780507 article EN cc-by Frontiers in Oncology 2021-12-24

Extramedullary hematopoiesis (EMH) is a rare cause of spinal cord compression defined as finding hematopoietic elements outside the physiological location in bone marrow. We report case 70-year-old man with JAK 2 positive myeloproliferative syndrome type polycythemia vera (PV), initially treated hydroxyurea. Two years after diagnosis, he presented progression biological and clinical evolution associating hyperleukocytosis hepatosplenomegaly no evidence acute myeloid leukemia. Treatment...

10.1016/j.ctro.2022.09.009 article EN cc-by-nc-nd Clinical and Translational Radiation Oncology 2022-10-03

Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG80, tumor-promoting peptide present in the blood of patients various cancers that has been shown to value. We evaluated value plasma hPG80 isocitrate dehydrogenase-wild type glioblastoma after surgery.A multicentric retrospective study treated standard radio-chemotherapy was conducted. The levels were measured EDTA samples collected surgery an ELISA...

10.1016/j.esmoop.2023.101626 article EN cc-by-nc-nd ESMO Open 2023-09-13

Brain metastases or primary brain tumours had poor prognosis until the use of high dose radiotherapy. However, radionecrosis is a complex challenge in post-radiotherapy management these patients due to difficulty distinguishing this complication from local tumour recurrence. MRI alone has variable specificity and sensibility, as does PET-CT imaging. We aimed investigate diagnostic performance dual-phase

10.3390/cancers16183216 article EN Cancers 2024-09-21

<title>Abstract</title> <bold>Purpose:</bold> Radionecrosis is a complex challenge in the post-radiotherapy management of these patients due to difficulty distinguish this complication from local tumour recurrence. MRI alone have variable specificity and sensibility as well PET-CT imaging. We aimed investigate diagnostic performance dual-phase [18F]-FDG PET-MRI cerebral radionecrosis tumor recurrence after cranial radiotherapy. <bold>Materials Methods:</bold> A retrospective analysis was...

10.21203/rs.3.rs-4232822/v1 preprint EN cc-by Research Square (Research Square) 2024-04-19

2049 Background: hPG 80 (circulating progastrin) is a protein secreted by many cancer types, playing role in tumorigenesis regulating stem cells, angiogenesis, proliferation/differentiation and decreasing apoptosis. detectable plasma of patients previous studies have shown its prognostic various cancers. Given the lack circulating biomarker glioblastoma, we evaluated value with IDH wild type glioblastoma Methods: This multicentric retrospective study included IDHwt treated standard...

10.1200/jco.2022.40.16_suppl.2049 article EN Journal of Clinical Oncology 2022-06-01
Elie Rassy Jean‐Michel Heard Fabrice André Kaiser G. Lim C. Benedikt Westphalen and 95 more Anna S. Berghoff Claudia Cardone E. Sander Connolly Deniz Can Güven Maria Kfoury Emre Kocakavuk Pablo Mandó Elene Mariamidze Alexios Matikas Myrto Moutafi Christoph Oing Rille Pihlak Kevin Punie Rodrigo Sánchez-Bayona Paweł Sobczuk Angelika M. Starzer A Teči C Vuger Haiyan Zhu Mel Valerie B. Cruz-Ordinario S.C. Altuna R. Canário Peter Vuylsteke Sujit Banerjee Evandro de Azambuja Andrés Cervantes Matteo Lambertini Joaquı́n Mateo Teresa Amaral Maria Alice Franzoi Emma Gillanders Inês Vaz-Luís Ilana Schlam Melody Menezes Chiara Corti Aihua Tan I. Abuali S Tolaney M Sampetrean C. Aldea T. Grinda Barbara Pistilli Juan B. Rodríguez Santiago Ponce-Aix Manuel Scimeca Rita Bonfiglio Wilbert Zwart E. Dijkstra Hein Putter Corrie A.M. Marijnen Per J. Nilsson C. van de Velde Boudewijn van Etten Geke A.P. Hospers Bengt Glimelius John J. Socha Wojtek P. Michalski Krzysztof Bujko Émilie Le Rhun Michael Weller Martin J. van den Bent Dieta Brandsma Julia Furtner Roberta Rudà Dirk Schadendorf Joan Seoane J. C. Tonn Pieter Wesseling Wolfgang Wick Giuseppe Minniti Solange Peters Giuseppe Curigliano Matthias Preusser Ludovic Doucet Axel Cailleteau Loïg Vaugier Carole Gourmelon M. Bureau Céline Salaud Vincent Roualdes Éric Samarut Maud Aumont M. Zenatri Delphine Loussouarn Véronique Quillien François Bocquet Léa Payen-Gay Dominique Joubert Alexandre Prieur M.F. Robert Jean‐Sébastien Frénel Felipe Roitberg Nathan I. Cherny R. Giuliani N.J. Latino M. Galotti

Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer?No, it does not.

10.1016/s2059-7029(23)01296-6 article EN cc-by-nc-nd ESMO Open 2023-10-01

Background: Inflammatory breast cancer (IBC) is a rare subtype with poor prognosis. Pathological complete response (pCR) has already been proposed as being predictor of survival, but the data are not specific to IBC, and prognostic value surrogacy partial pathological have rarely addressed. Thus, we aimed analyse survival outcomes patients nonmetastatic IBC. We also investigated tumour or nodal responses for each IBC subtype, including triple-negative (TN-IBC). Methods: In this retrospective...

10.2139/ssrn.4062758 article EN SSRN Electronic Journal 2022-01-01
Coming Soon ...